Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
CD4+ T cells in cancer
Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …
Regulatory mechanisms of PD-1/PD-L1 in cancers
Immune evasion contributes to cancer growth and progression. Cancer cells have the ability
to activate different immune checkpoint pathways that harbor immunosuppressive functions …
to activate different immune checkpoint pathways that harbor immunosuppressive functions …
Immune determinants of the pre-metastatic niche
Primary tumors actively and specifically prime pre-metastatic niches (PMNs), the future sites
of organotropic metastasis, preparing these distant microenvironments for disseminated …
of organotropic metastasis, preparing these distant microenvironments for disseminated …
A nitric-oxide driven chemotactic nanomotor for enhanced immunotherapy of glioblastoma
H Chen, T Li, Z Liu, S Tang, J Tong, Y Tao… - Nature …, 2023 - nature.com
The major challenges of immunotherapy for glioblastoma are that drugs cannot target tumor
sites accurately and properly activate complex immune responses. Herein, we design and …
sites accurately and properly activate complex immune responses. Herein, we design and …
Pancreatic cancer stroma: an update on therapeutic targeting strategies
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in
the Western world with limited therapeutic options and dismal long-term survival. The …
the Western world with limited therapeutic options and dismal long-term survival. The …
Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
Cancer immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the
treatment of advanced cancers. However, the tumor microenvironment (TME) functions as a …
treatment of advanced cancers. However, the tumor microenvironment (TME) functions as a …
Anti-angiogenic agents—overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
Immune checkpoint inhibitors have revolutionized medical oncology, although currently only
a subset of patients has a response to such treatment. A compelling body of evidence …
a subset of patients has a response to such treatment. A compelling body of evidence …
Targeting the tumour vasculature: from vessel destruction to promotion
As angiogenesis was recognized as a core hallmark of cancer growth and survival, several
strategies have been implemented to target the tumour vasculature. Yet to date, attempts …
strategies have been implemented to target the tumour vasculature. Yet to date, attempts …
Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer
CD4 T cells have been implicated in cancer immunity for their helper functions. Moreover,
their direct cytotoxic potential has been shown in some patients with cancer. Here, by mining …
their direct cytotoxic potential has been shown in some patients with cancer. Here, by mining …
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Multiple nanotherapeutics have been approved for patients with cancer, but their effects on
survival have been modest and, in some examples, less than those of other approved …
survival have been modest and, in some examples, less than those of other approved …